The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma

Cancer

Volumn 103, Issue 7, 2005, Pages 1336-1346

  Shapira, Ma'anit ^a   Ben Izhak, Ofer ^a   Linn, Shai ^a   Futerman, Boris ^a   Minkov, Ira ^a   Hershko, Dan D ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Cks1; Colorectal carcinoma; Cyclin kinase subunit 1; p27Kip1; Prognosis; S phase kinase associated protein 2; Skp2; Ubiquitin

Indexed keywords

ANTIBODY; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN CKS1; S PHASE KINASE ASSOCIATED PROTEIN 2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; ENZYME SUBUNIT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

AGED; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 15744382959     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20917     Document Type: Article

References (26)

1. th edition). New York: Lippincott, 1992.
2. Klump B, Nehls O, Okech T, et al. Molecular lesions in colorectal cancer. Impact on prognosis? Int J Colorectal Dis. 2004;19:23-42.
3. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 1997;3:231-234.
4. Kip1 inhibitor protein: prognostic implications in primary breast cancer. Nature Med. 1997;3:227-230.
5. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998;58:542-548.
6. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
7. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269: 682-685.
8. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425-479.
9. Carrano AC, Eytan E, Hershko A, Pagano M. Skp2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1:193-199.
10. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999; 1:207-214.
11. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF-(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 1999;9:661-664.
12. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol. 1999;15:435-467.
13. Hershko D, Bornstein G, Ben-Izhak O, et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer. 2001;91:1745-1751.
14. Ganoth D, Bornstein G, Ko TK, et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol. 2001;3:321-324.
15. Spruck C, Strohmaier H, Watson M, et al. CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell. 2001;7:639-650.
16. Shapira M, Ben-Izhak O, Bishara B, et al. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer. 2004;100:1615-1621.
17. Darwish H, Trejo IE, Shapira I, et al. Fighting colorectal cancer: molecular epidemiology differences among Ashkenazi and Sephardic Jews and Palestinians. Ann Oncol. 2004;13:1497-1501.
18. Signoretti S, Di Marcotullio L., Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002;110:633-641.
19. Ben-Izhak O, Lahav-Baratz S, Meretyk S, et al. Inverse relationship between Skp2 ubiqertin ligase and the cyclin dependent kinase inhibitor p27Kip in prostate cancer. J Urol. 2003;170:241-245.
20. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takashi T. High expression of S-phase kinase- interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 2001;61:7044-7047.
21. Masuda T-a, Inoue H, Nishida K, et al. Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res. 2003;9:5639-5698.
22. Schwander O, Bruch HP, Broll R. p21, p27, cyclin D1 and p53 in rectal cancer: immunohistochemistry with prognostic significance? Int J Colorectal Dis. 2002;17:11-19.
23. Gunther K, Dimmler A, Rodel F, et al. p27 does not predict histopathological response to radiochemotherapy in rectal cancer. J Surg Res. 2003;113:179-188.
24. Nalepa G, Harper JW. Therapeutic anti-cancer targets upstream the proteasome. Cancer Treat Rev. 2003;29:49-57.
25. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
26. Aghajanian C, Soignet S, Dizo DS, et al. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505-2511.